Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03101371 · ClinicalTrials.gov registry record · Phase 2

Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion

A Phase 2 study, sponsored by University of Colorado, Denver.

Completed
Registry status
Phase 2
Development phase
99
Enrollment target

NCT03101371: Completed Phase 2 study, sponsored by University of Colorado, Denver.

NCT03101371 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 99 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03101371, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
Phase 2
Development phase
99 participants
Enrollment target

Study Summary

Urinary Tract Infection (UTI) complications following catheter use in surgical patients remains high. Using an aseptic protocol has been shown to drastically reduce UTI incidence by 50%. Reducing UTIs will prevent extended hospital stays, readmission, and antibiotic use associated with this complication and improve cost-effectiveness of care. The investigators hypothesize that they can reduce the incidence of UTIs after catheter placement with the implementation of a Quality Improvement (QI) protocol to prevent excess exposure to the environment exposure of the catheter before, during and after insertion.

Primary Outcome

Participants were monitored for up to 14 days. This was assessed with a rapid urine analysis (UA) test. A urinary tract infection was defined as \>10\^5 bacterial colony forming units per ML on urine culture regardless of symptoms. This is the number of participants who had at least one CAUTI during the time of observation.

Interventions

  • DRUG Catheter insertion with Povidone Iodine
  • PROCEDURE Standard of care catheter insertion

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2017-10-10
Est. Completion 2019-02-15
Phase Phase 2
University of Colorado, Denver

1,283 total trials

What the finished NCT03101371 record still lists

NCT03101371 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower).

The record links to 0 conditions, and to 2 interventions - of which Catheter insertion with Povidone Iodine is the first listed.

NCT03101371 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03101371 about?

NCT03101371 is a clinical study titled "Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion". Urinary Tract Infection (UTI) complications following catheter use in surgical patients remains high. Using an aseptic protocol has been shown to drastically reduce UTI incidence by 50%. Reducing UTIs will prevent extended hospital stays, readmission, and antibiotic use associated with this complica...

What is the current status of trial NCT03101371?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2017-10-10. Estimated completion is 2019-02-15.

What interventions are being tested in trial NCT03101371?

The interventions under investigation include: Catheter insertion with Povidone Iodine (DRUG), Standard of care catheter insertion (PROCEDURE).

Who is sponsoring clinical trial NCT03101371?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03101371's enrollment target sits among peer trials

99 738th of 2000 higher than 1,258 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03965234 · 99 participants · Phase 1

    Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

  • NCT04022616 · 99 participants

    Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

  • NCT04042844 · 99 participants · Phase 2

    A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

  • NCT04143724 · 99 participants · Phase 2

    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03101371, the US trial registry maintained by the National Library of Medicine. NCT03101371 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.